- Strong Q1 Results: Adtalem Global Education (NYSE: ATGE) reported fiscal Q1 2026 adjusted earnings of $1.75 per share, up 35.7% year-over-year, on revenue of $462.3 million (+10.8% YoY) [1] [2]. Both metrics beat analyst expectations, and full-year guidance was reaffirmed at $7.60–$7.90 EPS on $1.90–$1.94 billion revenue [3].
- Stock Hits High, Then Craters: ATGE stock reached a new 52-week high of $156.26 in late October [4]. However, after the Q1 earnings release, shares plunged ~27% on Oct 31, trading around $102 intraday [5]. In the final minutes of Oct 30, the stock was $141.77 (up 56% year-to-date and 73% year-over-year) [6], meaning the post-earnings sell-off sharply cut those gains.
- Insider & Analyst Signals: Despite strong results, insider selling has spooked investors. A director recently sold ~25,500 shares at ~$132 [7], and overall insider sentiment turned negative with multiple insider sales in the last 3 months [8] [9]. Analysts remain mostly bullish – Barrington Research raised its price target from $150 to $170 (Outperform) [10], seeing robust earnings, while Baird lowered its target to $163 citing “execution issues” in Adtalem’s Chamberlain nursing programs [11]. Overall, 4 of 5 analysts rate ATGE a Buy, with a consensus Moderate Buy and ~$146 average target [12] [13].
- Current Metrics: After the drop, Adtalem’s market capitalization stands near $3.7 billion [14]. The valuation appears reasonable at roughly 15× trailing earnings (P/E ~15) and a PEG ratio ~1.3 [15] [16]. The company’s balance sheet is healthy (net debt leverage only 0.6× EBITDA [17], debt-to-equity ~0.5 [18]) with strong profitability (TTM 19% operating margin, 13% net margin) [19] [20]. Technical indicators show the stock entering oversold territory (RSI ~40) after the plunge [21].
- Executive Commentary: CEO Steve Beard called Q1 FY26 an “outstanding start,” highlighting nine consecutive quarters of enrollment growth and strong free cash flow fueling both growth investments and shareholder returns [22]. “Our focus remains singular: creating sustainable, long-term shareholder value by serving as essential talent infrastructure for America’s healthcare workforce,” Beard said [23]. Management maintained confidence in Adtalem’s strategy and noted an upcoming Investor Day on Feb 24, 2026 to detail its vision and capital allocation plans [24].
- Sector Leadership: Adtalem is the largest healthcare educator in the U.S., with ~97,000 students across its institutions [25] [26]. In fiscal 2025 the company served 91,780 students and graduated 29,000 healthcare professionals, directly helping to fill critical nurse and physician shortages [27]. Its flagship Chamberlain University (nursing school) and Walden University (online graduate programs) have driven consistent double-digit enrollment growth [28]. This focus on healthcare sets Adtalem apart from other for-profit education peers. (By comparison, Grand Canyon Education’s market cap is ~$5.7B and Graham Holdings ~$4.5B [29], but those peers lack Adtalem’s exclusive concentration in medical and nursing fields.) Adtalem’s scale is “category-defining”, producing about 21% of the nation’s nursing graduates with bachelor’s degrees, who are 1.5× more likely to secure full-time jobs than peers [30].
- Recent Developments: On October 15, Adtalem announced a partnership with Google Cloud to co-develop a first-of-its-kind AI credentials program for healthcare students and clinicians [31] [32]. This move underscores Adtalem’s push to integrate AI and technology in its curriculum. The company also expanded a dozen specialized nursing tracks and international medical education pathways in recent months [33] [34]. Additionally, Adtalem has a $150 million share buyback in place (about $142 million remaining through 2028) to return capital to shareholders [35].
Q1 Earnings Highlights and Stock Reaction
Robust Q1 FY2026 Results: Adtalem’s earnings for the quarter ended Sept 30, 2025 impressed on many fronts. Revenue came in at $462.3 million, up 10.8% year-over-year [36], while adjusted net income rose to $64.9 million (from $50.5M) [37]. Adjusted earnings were $1.75 per share, a 35.7% YoY jump [38], handily beating the consensus estimate of ~$1.57. GAAP EPS was $1.67 vs $1.18 in the prior-year quarter [39]. Importantly, enrollments continued to climb, with total student enrollment up 8.0% from last year [40] – marking Adtalem’s ninth straight quarter of growth, a rare streak in the education industry. The Chamberlain nursing program grew enrollment +2.2%, Walden University +13.6% (hitting record-high enrollment), and the Medical & Veterinary schools +2.4% [41]. Adjusted EBITDA increased to $112.0M with a solid 24.2% margin [42], reflecting improved operating leverage.
Table: Q1 FY2026 vs Q1 FY2025 – Key Financials (Sept quarter, in millions except per-share) [43] [44]
| Metric | Q1 FY2026 (Sep 2025) | Q1 FY2025 (Sep 2024) | Change (YoY) |
|---|---|---|---|
| Revenue | $462.3 M | ~$417 M (est.) | +10.8% [45] |
| Operating Income | $90.3 M (adj.¹) | $75.8 M (adj.¹) | +19.1% |
| Net Income | $61.8 M (GAAP) | $46.2 M (GAAP) | +33.8% |
| Earnings Per Share | $1.75 (adjusted) | $1.29 (adjusted) | +35.7% [46] |
| Adjusted EBITDA | $112.0 M (24.2% margin) | $96.7 M (23.2% margin) | +15.8% |
¹ Adjusted figures exclude one-time items. Source: Company press release [47] [48].
Adtalem also maintained its full-year outlook for FY2026, projecting $1.90–$1.94 billion revenue and $7.60–$7.90 in adjusted EPS [49]. If achieved, the low end would represent roughly ~14% EPS growth over the $6.67 adjusted EPS in FY2025 [50] [51]. The reiterated guidance signaled management’s confidence in sustained enrollment momentum and cost discipline.
Market Reaction – From Euphoria to Sell-Off: Given these bullish numbers, one might expect the stock to jump – and indeed, ATGE had been on a tear leading into the report. On October 25, shares hit an all-time 52-week high of $156.26, and closed that day at $154.71 [52]. Investors bid up the stock in anticipation of strong earnings and growth. However, when Q1 results actually landed on Oct 30, the immediate reaction was surprisingly negative. The stock slid ~6–7% in the next trading session (Oct 30), falling from about $153 to $143 [53] [54]. Then on October 31, the sell-off intensified — ATGE opened sharply lower and by mid-morning was down nearly 30%. Shares traded as low as $102.31, a one-day crash of -27.8% [55]. Volume spiked as some investors rushed for the exits.
This dramatic reversal erased roughly $1.5 billion in market value in a day, bringing Adtalem’s cap to ~$3.7B [56] from above $5B earlier in the week. Notably, even after this plunge, ATGE stock remained up about 12% year-to-date (having been +56% YTD before) and +40% or more over the past 12 months – still outperforming the broader market by a wide margin [57]. But for recent buyers at $150+, the pullback was painful.
Why the Stock Plunged: Several factors likely contributed to the post-earnings sell-off, despite no obvious bad news in the results. Valuation and profit-taking may have played a role – Adtalem’s stock had risen ~75% in one year [58], so some investors took profits on the strong report. More specifically, insider activity and mixed analyst signals created jitters:
- Insider Selling: In the months prior, insiders were selling shares, which can be a red flag. Former CEO (now director) Lisa Wardell disclosed selling ~$2.49 million worth of stock in late August [59] [60], and multiple insiders sold in the $130s range. TipRanks noted “insider sentiment has turned negative with a rise in insider selling,” which “overshadowed the positive financial results” in some investors’ eyes [61]. Seeing leaders cash out near peak prices often raises concern that the stock’s best days (for now) might be behind it.
- Analyst Reactions: While one key analyst became more bullish (Barrington’s target hike to $170), another voice of caution emerged. Investment bank Baird reportedly lowered its price target to $163 for ATGE right after earnings, citing “execution issues at Chamberlain [University] post-licensure” programs [62]. Chamberlain’s post-licensure nursing courses (for advanced practice nurses) had softer growth than its pre-licensure programs [63], which could signal some operational hiccups. The mixed messaging – one firm raising targets, another trimming them – may have confused the market. Overall, however, Wall Street’s view on Adtalem remains positive, with multiple analysts reiterating Buy ratings and seeing the pullback as an opportunity. As of late October, ATGE had a consensus Moderate Buy rating and an average target price around $145–$150 [64] [65] (which is ~40% above the post-drop trading price).
- High Expectations: Adtalem’s stellar run-up meant expectations were sky-high. The company delivered strong growth, but anything short of “blow-out” might have disappointed momentum traders. It’s possible some investors expected even more upside or a guidance raise, given the 35% EPS jump. The reaffirmed guidance, while solid, implies the growth rate will moderate in coming quarters (to ~14–18% for the full year) [66]. That might have prompted some to lock in gains.
- Market Conditions: The broader stock market mood can’t be ignored. Late October 2025 saw volatility and sector rotations. On Oct 30, the S&P 500 fell ~1% and many high-flying stocks pulled back [67]. Education stocks can trade like consumer cyclicals, which were under pressure. If some algorithmic or momentum investors started selling, it could have cascaded given the lower trading liquidity in ATGE (the Oct 30 trading volume was 94% below average [68], indicating limited buyers at first). Once the price started falling fast on Oct 31, stop-loss orders may have triggered, exacerbating the drop.
The key point: no fundamental bombshell caused Adtalem’s plunge – it appears to be a combination of technical factors and sentiment. In fact, TipRanks’ market update succinctly stated that “despite strong Q1 financial performance…mixed signals in the market” (insider selling and split analyst opinions) led to the stock’s unusual volatility [69].
Analyst Opinions and Forecasts
Bull Case – Room to Rebound: Many analysts and experts see the sell-off as overdone given Adtalem’s fundamentals. Prior to the dip, research firm Simply Wall St noted ATGE was trading at about 33% below their intrinsic value estimate [70] and highlighted that “earnings grew by 69% over the past year” with a forecast of ~14% annual growth going forward [71]. The stock’s one-year gain of ~75% was driven by real earnings power, not hype. After the drop to ~$100, Adtalem’s valuation multiples have compressed – the forward P/E fell to the mid-teens, which is cheap for a company growing EPS double-digits and operating in a high-demand niche. The PEG ratio near 1.0–1.3 (price/earnings-to-growth) implies the stock is reasonably valued relative to its growth rate [72] [73]. Additionally, technical indicators suggest an oversold condition: the Relative Strength Index (RSI) dipped into the 40s (approaching typical oversold <30 range) [74], and the stock fell below its 50-day moving average of ~$141 [75] – potentially a mean-reversion opportunity for bargain hunters.
Barrington Research, which upped its price target to $170 on October 15, maintained an Outperform rating, implying confidence that Adtalem’s growth strategy will drive the stock higher [76]. On Oct 31, Barrington’s Alexander Paris reiterated his bullish stance, emphasizing the company’s competitive strengths [77]. The new $170 target is ~65% above the current price. Even the lowered Baird target of $163 is significantly higher (+60%) than $102 [78], suggesting that once the dust settles, the stock could regain lost ground.
Street Consensus: Out of 5 analysts tracked, four rate ATGE a Buy and one a Hold [79]. Before the earnings, the average target was around $145.67 [80]. This may be revised as analysts update models post-call, but so far commentary hasn’t turned negative. Zacks Investment Research, for example, highlighted that Adtalem “delivered earnings and revenue surprises of +11.46% and +1.45%” in Q1 and noted the company’s ongoing efficiency improvements [81]. TipRanks data still shows a “Technical Sentiment: Buy” for ATGE stock and a YTD performance of +52% (prior to the drop) [82], indicating that momentum and fundamentals were strong before this hiccup.
Bear/Bearish View – Execution Risks: The main cautionary views focus on execution and sector-specific risks. Baird’s mention of “execution issues at Chamberlain post-licensure” hints that not all parts of Adtalem’s business are firing perfectly [83]. Chamberlain University’s nursing enrollment grew 5.8% in FY2025 (and 2.2% in the latest quarter) [84], mainly through pre-licensure (entry-level) programs, whereas advanced nursing programs have plateaued. If Adtalem cannot continue to scale those higher-margin programs, revenue mix could shift. Additionally, for-profit educators always face regulatory and political risk. Changes in student loan policy or accreditation rules can impact enrollment. However, Adtalem’s focus on healthcare, where demand is secular and outcomes (jobs for graduates) are strong, somewhat insulates it from the traditional for-profit college scrutiny. As noted in an industry study, for-profit institutions account for 21% of nursing BSN graduates nationwide, filling 17% of total demand, and Adtalem’s graduates have good employment rates [85]. This gives the company a compelling story to tell regulators and investors alike about the social value it provides.
Another concern for some investors is whether growth can continue at this pace. The Q1 revenue jump of ~11% is impressive, but partly aided by the Walden University acquisition (completed in 2021) now hitting its stride. As those comps normalize, Adtalem may not sustain double-digit growth every quarter. The company’s own FY26 guidance of ~6.5%–9% revenue growth [86] is more modest than last year’s 12.9%. If growth were to slip below that range or if enrollment trends weaken, the market could reassess the premium multiple it previously awarded. For now, though, all signals (enrollments, applications, student retention) appear solid according to management’s commentary.
Big Picture – Outlook: The consensus among analysts is that Adtalem’s long-term thesis is intact. A SimplyWallSt analysis on Oct 14 even posited that a “near-term pullback could set up a strong long-term rally” in ATGE [87]. That was written before the recent drop – and indeed that pullback has now materialized, potentially giving long-term investors a chance to buy in at a discount. The average price target being in the $150+ range suggests analysts see the stock recovering and then some.
The upcoming Investor Day in February 2026 will be a key event to watch. Adtalem’s CEO and team are expected to lay out their multi-year vision, possibly including new expansion initiatives, technology integrations (such as the Google Cloud AI partnership), and uses of cash (M&A or further buybacks/dividends). Any upbeat forecasts or strategic partnerships announced there could be catalysts for the stock.
Company’s Role in Education & Competitive Landscape
Adtalem Global Education is not just another for-profit college operator; it has transformed itself into a healthcare education powerhouse. The Chicago-based company (formerly known as DeVry Education Group) divested its non-healthcare businesses over the past decade and doubled down on medical and nursing schools. Today Adtalem owns:
- Chamberlain University – one of the largest nursing schools in the U.S., with over 40,000 students. Chamberlain offers nursing degrees from bachelor’s through doctorate, and has been expanding with an online BSN program to reach students in 36 states [88]. It’s a key supplier of new nurses nationally.
- Walden University – an online-focused university acquired in 2021, offering graduate degrees in nursing, health sciences, counseling, and other fields. Walden has grown its enrollment 10%+ each quarter, now above 48,000 students [89] [90]. This gives Adtalem a strong foothold in online higher ed, a segment with scalability.
- Medical and Veterinary Schools – including Ross University School of Medicine and Ross University School of Veterinary Medicine (both in the Caribbean), and American University of the Caribbean (AUC) School of Medicine. These institutions collectively enroll ~5,000 future doctors and veterinarians [91]. They cater to U.S. and international students aiming to become MDs and DVMs, and help address physician shortages (especially in primary care).
- Other smaller healthcare-related programs and certificates, including partnerships for continuing education.
By focusing on healthcare, Adtalem taps into a strong secular trend: an aging population and persistent shortages of healthcare professionals (nurses, physicians, etc.). The company frequently highlights that demand for its graduates is very high – hospitals, clinics, and other employers actively recruit from Adtalem’s institutions. In Steve Beard’s words, Adtalem serves as “essential talent infrastructure for America’s healthcare workforce” [92]. This mission-driven angle not only underpins the growth story (more students enrolling to pursue in-demand careers), but also distinguishes Adtalem from some peers whose programs in general business or liberal arts might not have the same tailwinds.
Competitive Comparison: In the for-profit education sector, Adtalem’s closest comparables are other post-secondary education companies, though none have the exact same focus:
- Grand Canyon Education (NASDAQ: LOPE): Operates Grand Canyon University, a formerly for-profit Christian university (now non-profit, with GCE providing services). Market cap ~$5.7B [93]. While GCU has nursing and healthcare programs, it’s a broader institution. GCE’s growth has been more modest (single-digit revenue growth) and its stock up ~20% YTD, trailing ATGE. Adtalem’s pure-play healthcare emphasis arguably gives it an edge in growth and investor appeal.
- Strategic Education (NASDAQ: STRA): Owner of Strayer and Capella Universities, focusing on business, IT, and some nursing programs. Market cap ~$1.9B; STRA’s growth has been flat to low-single-digits recently. It doesn’t have the same exposure to healthcare education demand as Adtalem.
- Perdoceo Education (NASDAQ: PRDO): Runs Colorado Technical University and American InterContinental University (mostly online business/IT programs). Market cap ~$2.3B. PRDO’s stock is up in 2025 as well, but the company is smaller and not in the medical field.
- Graham Holdings (NYSE: GHC): A conglomerate that owns Kaplan (test prep and some higher-ed programs) among many assets. Kaplan’s scale and growth don’t match Adtalem’s. GHC’s education segment is a smaller piece of its business (market cap ~$4.5B overall) [94].
In summary, Adtalem is carving out a dominant position in the healthcare education niche, which comes with high barriers to entry (you need accreditation, clinical training partnerships, etc. to operate med and nursing schools). This gives it a kind of competitive moat relative to would-be new entrants. Non-profit universities and public schools certainly compete (state universities have nursing programs, for example), but the demand is so large that Adtalem has plenty of room to grow without directly taking share from others – it is mostly filling an overall shortage gap. Lightcast research cited by Adtalem shows that for-profit institutions (like Adtalem’s schools) supply a significant chunk of the nursing workforce and that their graduates have strong outcomes [95]. This suggests Adtalem’s model is increasingly accepted as part of the solution to national healthcare staffing needs.
One area to watch in the competitive landscape is education technology (EdTech) partnerships. The recent Google Cloud partnership is a notable example: Adtalem is partnering with a tech giant to create an AI curriculum for healthcare professionals [96]. This could keep Adtalem’s offerings cutting-edge and attractive to students (and employers) looking for modern skills. Competitors might seek similar alliances; whoever integrates AI and simulation technology best into their training could have an edge in producing job-ready graduates. Adtalem’s med schools are already partnering with hospitals (e.g., AUC with University of Wolverhampton and Mass General for tech training [97]) and healthcare companies (like its new program with ScribeAmerica for medical scribes). These ties further entwine Adtalem with industry needs, potentially giving it a pipeline advantage over more academically isolated institutions.
Finally, Adtalem’s track record of “disciplined capital allocation” [98] merits mention. In FY2025 it generated $283M in free cash flow and returned $211M to shareholders via buybacks [99]. The board authorized a new $150M share repurchase (about 4% of outstanding shares) through 2028 [100]. This indicates confidence in the company’s financial health and provides support to the stock over time (indeed, Adtalem even bought back $8M of stock in Q1 at presumably higher prices [101]). Such financial strength is somewhat unusual in the education sector, where many players carry higher debt or thinner margins. Adtalem’s net debt/EBITDA below 1× and interest rate reductions on its loans [102] show prudent management. These factors position Adtalem to continue investing in growth (new programs, capacity expansions) while rewarding shareholders – a balance that bodes well if executed properly.
Conclusion
Bottom Line: Adtalem Global Education has emerged as a leader in the healthcare education space, benefiting from powerful tailwinds (the urgent need for nurses, doctors, and healthcare tech talent) and demonstrating the ability to scale up programs to meet that demand. The first quarter of fiscal 2026 showcased double-digit growth in revenue and student enrollments, with management reaffirming a bullish outlook for the full year [103]. Despite this operational strength, ATGE’s stock price experienced a sharp and puzzling drop in late October. Short-term traders were rattled by a combination of profit-taking, insider sales, and cautious commentary, but no fundamental weaknesses in the business were reported.
For investors, the recent volatility presents both risks and potential rewards. The risk is that momentum-driven selling could continue in the near term, or that unforeseen challenges (regulatory, enrollment, etc.) could arise. However, many analysts see the sell-off as a buying opportunity, given Adtalem’s solid financial footing and growth prospects. “While Adtalem faces short-term stock price volatility, its robust financial health and strong market positioning provide a solid foundation for future performance,” as GuruFocus summarized after the drop [104]. The stock now trades at valuations that value investors might find attractive relative to its earnings trajectory.
Investors should watch upcoming events like the Q1 earnings call transcript (for details on any soft spots like Chamberlain’s post-licensure issue) and the February 2026 Investor Day for clues on how Adtalem will sustain its momentum. Key metrics to monitor include continued enrollment growth (especially in nursing and medical programs), profit margins amid expansion, and the company’s capital deployment (share buybacks and possible dividends or acquisitions).
In the broader context, Adtalem’s focus on healthcare education positions it as a mission-critical player in addressing the nation’s healthcare workforce gap. That societal need isn’t going away – which means Adtalem’s core business has a degree of resilience and long-term relevance that many education companies lack. If management can navigate execution challenges and keep outcomes strong (so that students graduate and get those healthcare jobs), Adtalem is poised to thrive in the years ahead.
Sources:
- Associated Press – “Adtalem: Fiscal Q1 Earnings Snapshot” (Oct 30, 2025) [105] [106]
- Business Wire – Adtalem Global Education Q1 FY2026 Results Press Release (Oct 30, 2025) [107] [108]
- MarketBeat – “ATGE Sets New 1-Year High – Time to Buy?” (Oct 25, 2025) [109] [110]; “ATGE Shares Down 6.7% – Here’s Why” (Oct 30, 2025) [111] [112]
- GuruFocus – “ATGE Shares Plummet Over 27%” (Oct 31, 2025) [113] [114]
- TipRanks – “Why Adtalem Global Education Shares Are Tumbling” (Oct 31, 2025) [115] [116]
- Simply Wall St via Yahoo Finance – Analyst and Performance Overview (Oct 6, 2025) [117] [118]
- Adtalem Investor Relations – Fiscal 2025 Results Press Release (Aug 7, 2025) [119] [120]; Newsroom Article on FY2025 (Aug 7, 2025) [121] [122]
- Lightcast research via Career.org – Impact of For-Profit Healthcare Education (2025) [123].
References
1. www.businesswire.com, 2. www.ctpost.com, 3. www.ctpost.com, 4. www.marketbeat.com, 5. www.gurufocus.com, 6. www.ctpost.com, 7. www.marketbeat.com, 8. www.gurufocus.com, 9. www.tipranks.com, 10. www.marketbeat.com, 11. www.tipranks.com, 12. www.marketbeat.com, 13. www.marketbeat.com, 14. www.gurufocus.com, 15. www.marketbeat.com, 16. www.gurufocus.com, 17. www.businesswire.com, 18. www.gurufocus.com, 19. www.gurufocus.com, 20. www.gurufocus.com, 21. www.gurufocus.com, 22. www.businesswire.com, 23. www.businesswire.com, 24. www.businesswire.com, 25. www.businesswire.com, 26. www.businesswire.com, 27. www.adtalem.com, 28. www.businesswire.com, 29. simplywall.st, 30. www.adtalem.com, 31. www.marketscreener.com, 32. www.businesswire.com, 33. www.businesswire.com, 34. www.businesswire.com, 35. www.businesswire.com, 36. www.businesswire.com, 37. www.businesswire.com, 38. www.businesswire.com, 39. www.businesswire.com, 40. www.businesswire.com, 41. www.businesswire.com, 42. www.businesswire.com, 43. www.businesswire.com, 44. www.businesswire.com, 45. www.businesswire.com, 46. www.businesswire.com, 47. www.businesswire.com, 48. www.businesswire.com, 49. www.ctpost.com, 50. investors.adtalem.com, 51. investors.adtalem.com, 52. www.marketbeat.com, 53. www.marketbeat.com, 54. www.marketbeat.com, 55. www.gurufocus.com, 56. www.gurufocus.com, 57. www.ctpost.com, 58. simplywall.st, 59. www.marketscreener.com, 60. www.gurufocus.com, 61. www.tipranks.com, 62. www.tipranks.com, 63. www.businesswire.com, 64. www.marketbeat.com, 65. www.marketbeat.com, 66. investors.adtalem.com, 67. tradingeconomics.com, 68. www.marketbeat.com, 69. www.tipranks.com, 70. simplywall.st, 71. simplywall.st, 72. www.marketbeat.com, 73. www.gurufocus.com, 74. www.gurufocus.com, 75. www.marketbeat.com, 76. www.marketbeat.com, 77. www.gurufocus.com, 78. www.tipranks.com, 79. www.marketbeat.com, 80. www.marketbeat.com, 81. finance.yahoo.com, 82. www.tipranks.com, 83. www.tipranks.com, 84. www.businesswire.com, 85. www.adtalem.com, 86. www.businesswire.com, 87. simplywall.st, 88. www.businesswire.com, 89. investors.adtalem.com, 90. www.adtalem.com, 91. investors.adtalem.com, 92. www.businesswire.com, 93. simplywall.st, 94. simplywall.st, 95. www.adtalem.com, 96. www.marketscreener.com, 97. www.businesswire.com, 98. www.businesswire.com, 99. www.adtalem.com, 100. investors.adtalem.com, 101. www.businesswire.com, 102. investors.adtalem.com, 103. www.ctpost.com, 104. www.gurufocus.com, 105. www.ctpost.com, 106. www.ctpost.com, 107. www.businesswire.com, 108. www.businesswire.com, 109. www.marketbeat.com, 110. www.marketbeat.com, 111. www.marketbeat.com, 112. www.marketbeat.com, 113. www.gurufocus.com, 114. www.gurufocus.com, 115. www.tipranks.com, 116. www.tipranks.com, 117. simplywall.st, 118. simplywall.st, 119. investors.adtalem.com, 120. investors.adtalem.com, 121. www.adtalem.com, 122. www.adtalem.com, 123. www.adtalem.com